New Mexico Medical Psilocybin Act

Domain VII · Transpersonal, psychedelic & altered states · 2025 · New Mexico, USA

What it is

This is a state regulated-access programme, not a psychotherapy model. The Act creates a "medical use of psilocybin program" run by NMDOH's Center for Medical Cannabis and Psilocybin. Under it, qualified patients with a qualifying condition receive psilocybin from permitted producers, with "medical…

Format

• The clinician discusses risks and benefits, and attests to the diagnosis, its date and supporting documentation, medical appropriateness, and that likely benefits outweigh risks. They also give information about the Equity and Access Fund where it applies.
• The patient applies through NMDOH's electronic system with ID, a signed medical-information release, and an affirmation that they understand the risks and benefits discussed.

Who practises it, and how they are trained or regulated

• The regulator defines the stages of patient flow. It does not set clinical session counts for patients. Where counts appear below, they come from the practicum rules (training) or from research guidelines, and are labelled as such.
• Goal: identify a possible qualifying condition and connect the client with a certifying clinician.
• The draft requires an actual clinician–patient relationship. An outside psychotherapist cannot certify unless they also hold a licence to diagnose and a controlled-substance registration. Critics note that, under the draft, licensed professional clinical counsellors can deliver services but cannot sign certification.

Questions to explore with your client

• What drew you to it, and what are you hoping it will change?
• Is there physical contact? Was it explained beforehand, and do you feel free to say no or stop at any point?
• Does it involve any substance, plant preparation, remedy or supplement? Has your doctor or prescriber been told, especially about any medication you take?
• Does it involve intense or unusual breathing? Have you been told about the medical conditions for which that is not advised?
• Is it a group, retreat or community? How do they respond if someone wants to leave or raises a concern?
• Who runs it, and what training or registration do they hold?
• What actually happens in a session or meeting, and how often?
• What does it cost, and is there pressure to commit to more?
• How do you feel afterwards, in the hours and days that follow?
• Does it fit with, or clash with, the work we do here?

What practitioners of it watch for

• falls, and disorientation on the way back.
• facilitators taking on therapy or medical roles.
• no ride home arranged. Do not schedule the session until there is one.
• low mood, anxiety or confusion that persists, or perceptual disturbance.
• high-risk profiles, crisis after use, and pressure on you to facilitate.

When to involve someone else

• New or worsening physical symptoms, or advice to stop or change prescribed medication: involve the client's doctor or prescriber.
• Signs of coercion, isolation from family and friends, escalating costs or secrecy: discuss openly and consider safeguarding.
• A crisis or thoughts of suicide: follow your crisis protocol. In the US, call or text 988; in the UK and Ireland, Samaritans on 116 123.

Drawn automatically from the guide's own sections. Stay curious: neither endorse nor dismiss what the client values, and check anything that matters against the full guide and its sources. Not medical advice.